Arkgen Enterprises Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 18-12-2024
- Paid Up Capital ₹ 2.45 Cr
as on 18-12-2024
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue 54.79%
(FY 2022)
- Profit 91.19%
(FY 2022)
- Ebitda 6.33%
(FY 2022)
- Net Worth 34.92%
(FY 2022)
- Total Assets 99.59%
(FY 2022)
About Arkgen Enterprises
The Corporate was formerly known as Viziphar Biosciences Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.45 Cr, as per Ministry of Corporate Affairs (MCA) records.
Padiyath Akbarali and Hathika Akbarali serve as directors at the Company.
- CIN/LLPIN
U73100KA2005PTC037593
- Company No.
037593
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Nov 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Arkgen Enterprises?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Padiyath Akbarali  | Additional Director | 19-May-2016 | Current |
| Hathika Akbarali | Additional Director | 19-May-2016 | Current |
Financial Performance of Arkgen Enterprises.
Arkgen Enterprises Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 54.79% increase. The company also saw a substantial improvement in profitability, with a 91.19% increase in profit. The company's net worth Soared by an impressive increase of 34.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Arkgen Enterprises?
Unlock access to Arkgen Enterprises's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Arkgen Pharma Private LimitedActive 10 years 4 monthsPadiyath Akbarali and Hathika Akbarali are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Arkgen Enterprises?
Unlock and access historical data on people associated with Arkgen Enterprises, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Arkgen Enterprises, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Arkgen Enterprises's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
